Cempra’s Antibiotic Likely Needs Bigger Trial – But Might Be Able To Do It In Phase IV

FDA advisory committee votes 7-6 that the strong efficacy profile of Solithera (solithromycin) outweighs its unknown safety risks; panels agreed that more data was needed, but were split on whether it was needed pre- or post-approval.